Autolus Therapeutics plc
AUTL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001730463
In the last 90 days, Autolus Therapeutics plc insiders filed 0 open-market purchases and 1 sale; 83 institutions reported holding it in 13F filings for Q2 2026, worth $212.0M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Autolus Therapeutics plc as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 110
- +9 vs. Q3 2024
- Shares held
- 168.4M
- −10.2M (−5.7%) vs. Q3 2024
- Total value
- $395.4M
- −$253.1M (−39.0%) vs. Q3 2024
- New holders
- 23
- 34 more added
- Sold out
- 14
- 31 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AUTL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 83 | $212.0M |
| Q1 2026 | 84 | $184.4M |
| Q4 2025 | 89 | $277.1M |
| Q3 2025 | 96 | $235.7M |
| Q2 2025 | 94 | $378.6M |
| Q1 2025 | 95 | $261.0M |
| Q4 2024 | 110 | $395.4M |
| Q3 2024 | 101 | $648.5M |
| Q2 2024 | 111 | $620.0M |
| Q1 2024 | 120 | $1.12B |
| Q4 2023 | 99 | $746.6M |
| Q3 2023 | 71 | $258.1M |
| Q2 2023 | 69 | $260.4M |
| Q1 2023 | 65 | $195.1M |
| Q4 2022 | 71 | $204.2M |
| Q3 2022 | 66 | $105.7M |
| Q2 2022 | 67 | $143.9M |
| Q1 2022 | 66 | $228.6M |
| Q4 2021 | 73 | $272.3M |
| Q3 2021 | 59 | $164.2M |
| Q2 2021 | 69 | $169.6M |
| Q1 2021 | 63 | $129.4M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Autolus Therapeutics plc; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 4,500,000 | $10.6M | 1.65% | 00.0% | Unchanged |
| Frazier Life Sciences Management, L.P. | 4,623,324 | $10.9M | 0.45% | 00.0% | Unchanged |
| Polygon Management Ltd. | 8,250,000 | $19.4M | 6.26% | +250,000+3.1% | Added |
| Armistice Capital, LLC | 9,200,000 | $21.6M | 0.50% | +2,328,000+33.9% | Added |
| Avoro Capital Advisors LLC | 9,910,642 | $23.3M | 0.33% | −2,435,036−19.7% | Reduced |
| Deep Track Capital, LP | 14,218,903 | $33.4M | 1.25% | −1,053,269−6.9% | Reduced |
| FMR LLC | 15,632,270 | $36.7M | 0.00% | −2,141,603−12.0% | Reduced |
| Syncona Portfolio Ltd | 16,640,720 | $39.1M | 73.83% | −1,913,904−10.3% | Reduced |
| Blackstone Group Inc. | 20,485,611 | $48.1M | 0.23% | 00.0% | Unchanged |
| Wellington Management Group LLP | 25,345,680 | $59.6M | 0.01% | +1,125,454+4.6% | Added |
| Deerfield Management Company, L.P. (Series C) | 0 | $0 | 0.00% | −3,639,000−100.0% | Sold out |
| Adage Capital Partners GP, L.L.C. | 0 | $0 | 0.00% | −2,950,000−100.0% | Sold out |
| StemPoint Capital LP | 0 | $0 | 0.00% | −2,616,602−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −298,086−100.0% | Sold out |
| Octagon Capital Advisors LP | 0 | $0 | 0.00% | −176,000−100.0% | Sold out |
| Voloridge Investment Management, LLC | 0 | $0 | 0.00% | −121,035−100.0% | Sold out |
| TD Asset Management Inc | 0 | $0 | 0.00% | −98,406−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −91,687−100.0% | Sold out |
| Altfest L J & Co Inc | 0 | $0 | 0.00% | −21,820−100.0% | Sold out |
| Capstone Investment Advisors, LLC | 0 | $0 | 0.00% | −13,951−100.0% | Sold out |
| ProShare Advisors LLC | 0 | $0 | 0.00% | −11,796−100.0% | Sold out |
| Franklin Resources Inc | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Golden State Equity Partners | 0 | $0 | 0.00% | −3,900−100.0% | Sold out |
| NBC Securities, Inc. | 0 | $0 | 0.00% | −800−100.0% | Sold out |